Skip to main navigation Skip to search Skip to main content

Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen

  • Jonathan L. Finlay
  • , James M. Boyett
  • , Allan J. Yates
  • , Jeffrey H. Wisoff
  • , Jerrold M. Milstein
  • , J. Russell Geyer
  • , Salvatore J. Bertolone
  • , Patricia McGuire
  • , Joel M. Cherlow
  • , Melvin Tefft
  • , Patrick A. Turski
  • , William M. Wara
  • , Michael Edwards
  • , Leslie N. Sutton
  • , Mitchell S. Berger
  • , Fred Epstein
  • , Gregory Ayers
  • , Jeffrey C. Allen
  • , Roger J. Packer

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: In a previous randomized trial, the addition of adjuvant chemotherapy to postoperative radiotherapy proved beneficial in the treatment of childhood high-grade astrocytomas. The present study tests the hypothesis that an eight-drug adjuvant chemotherapy regimen would improve survival in such children compared with the three-drug regimen of the prior study. Patients and Methods: Between April 1985 and May 1990, patients between the ages of 18 months and 21 years with newly diagnosed high-grade astrocytomas were eligible for this study, as determined by the treating institution's histopathologic diagnosis. Treatment consisted of postoperative local-field radiotherapy and adjuvant chemotherapy, either lomustine (CCNU), vincristine, and prednisone (control regimen) or eight-drugs-in-1-day chemotherapy (experimental regimen). Two cycles of postoperative preirradiation chemotherapy were administered in the experimental regimen. Patients were evaluated radiographically every 3 months after irradiation. Results: Eighty- five eligible patients were randomized to the control regimen and 87 to the experimental regimen. The progression-free survival (PFS) and overall survival (OS) at 5 years were 33% (SE = 5%) and 36% (SE = 6%), respectively. There was no statistical difference in outcome between the two chemotherapy regimens. In patients with confirmed diagnoses of anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM), anaplastic astrocytoma, greater than 90% resection, and nonmidline tumor location were characteristics predictive of an improved PFS. There was a difference in toxicity between the two chemotherapeutic regimens, with greater myelosuppression and hearing loss in the experimental regimen. Tumor recurrence occurred primarily within the primary tumor site. Conclusions: There is no benefit to the treatment of high-grade astrocytomas in children with eight-drugs-in-1-day chemotherapy compared with CCNU, vincristine, and prednisone. Extent of tumor resection and histopathologic diagnosis are significant prognostic variables. The overall outcome for children with high-grade astrocytomas remains poor.

Original languageEnglish
Pages (from-to)112-123
Number of pages12
JournalJournal of Clinical Oncology
Volume13
Issue number1
DOIs
StatePublished - Jan 1995

Fingerprint

Dive into the research topics of 'Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen'. Together they form a unique fingerprint.

Cite this